Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Age is no longer a barrier to successful autologous hematopoietic cell transplantation (autoHCT). Improved stem cell mobilization and supportive care are potentially making autoHCT more feasible in elderly patients in recent years. However, reports of autoHCT outcomes in elderly patients aged 65 years-old (yo) and older are limited. These patients are underrepresented in clinical trials and data usually come from relatively small series and subgroup analyses in the main indications, namely multiple myeloma (MM) and lymphoproliferative disorders (LPD). Here, we sought to evaluate the feasibility and general outcomes of the autoHCT procedure in a large cohort of elderly patients reported to the EBMT.